These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2239475)

  • 21. Protective effect of selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208
    [No Abstract]   [Full Text] [Related]  

  • 22. The evolution and profile of dementia in Parkinson's disease.
    Ross HF; Hughes TA; Boyd JL; Biggins CA; Madeley P; Mindham RH; Spokes EG
    Adv Neurol; 1996; 69():343-7. PubMed ID: 8615150
    [No Abstract]   [Full Text] [Related]  

  • 23. [Levodopa dependency in Parkinson's disease: case report and review].
    Müller U; Reuter M; Hermann W; Gertz HJ
    Nervenarzt; 2002 Sep; 73(9):887-91. PubMed ID: 12215883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is ischemic cerebrovascular disease a risk factor for dementia in patients with Parkinson's disease?
    Papapetropoulos S; Villar JM; Mash DC
    Acta Neurol Scand; 2006 May; 113(5):353-4. PubMed ID: 16629774
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 26. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Memory and executive function impairment predict dementia in Parkinson's disease.
    Levy G; Jacobs DM; Tang MX; Côté LJ; Louis ED; Alfaro B; Mejia H; Stern Y; Marder K
    Mov Disord; 2002 Nov; 17(6):1221-6. PubMed ID: 12465060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan.
    Montastruc JL; Fabre N; Rascol O; Senard JM; Blin O
    Mov Disord; 1994 Mar; 9(2):242-3. PubMed ID: 8196695
    [No Abstract]   [Full Text] [Related]  

  • 29. Parkinson's disease.
    Clarke C; Moore A
    Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia.
    Noe E; Marder K; Bell KL; Jacobs DM; Manly JJ; Stern Y
    Mov Disord; 2004 Jan; 19(1):60-7. PubMed ID: 14743362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia.
    Pankratz N; Byder L; Halter C; Rudolph A; Shults CW; Conneally PM; Foroud T; Nichols WC
    Mov Disord; 2006 Jan; 21(1):45-9. PubMed ID: 16116614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
    Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L
    Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206
    [No Abstract]   [Full Text] [Related]  

  • 33. Smoking and cognitive function in Parkinson's disease.
    Weisskopf MG; Grodstein F; Ascherio A
    Mov Disord; 2007 Apr; 22(5):660-5. PubMed ID: 17266085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mental disorders in Parkinson's disease after treatment with L-DOPA.
    Rondot P; de Recondo J; Coignet A; Ziegler M
    Adv Neurol; 1984; 40():259-69. PubMed ID: 6695602
    [No Abstract]   [Full Text] [Related]  

  • 35. Combined effect of age and severity on the risk of dementia in Parkinson's disease.
    Levy G; Schupf N; Tang MX; Cote LJ; Louis ED; Mejia H; Stern Y; Marder K
    Ann Neurol; 2002 Jun; 51(6):722-9. PubMed ID: 12112078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical subtypes of Parkinson disease].
    Poewe W; Gerstenbrand F
    Wien Med Wochenschr; 1986 Aug; 136(15-16):384-7. PubMed ID: 3788189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements.
    Montastruc JL; Celsis P; Agniel A; Demonet JF; Doyon B; Puel M; Marc-Vergnes JP; Rascol A
    Mov Disord; 1987; 2(4):279-89. PubMed ID: 3509776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease.
    Burn DJ; McKeith IG
    Mov Disord; 2003 Sep; 18 Suppl 6():S72-9. PubMed ID: 14502659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa.
    Tan A; Salgado M; Fahn S
    Mov Disord; 1996 Mar; 11(2):214-6. PubMed ID: 8684394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.